Kindstar Globalgene Technology, Inc. (“Kindstar Global”, Stock Code: 09960.HK) completed its IPO and listing on the Main Board of the Hong Kong Stock Exchange on July 16, 2021, offering 226.405 million shares globally at HKD 9.78 per share. The net proceeds from the global offering are expected to be approximately HKD 2.0536 billion (excluding over-allotment). As the Chinese legal adviser to the underwriter, Jingtian & Gongcheng was engaged in the listing of Kindstar Global and provided one-stop legal services throughout the undertaking.

Kindstar Global is a leading provider of independent clinical esoteric testing services in China. Among all of the providers of independent esoteric testing in China, Kindstar Global has the largest esoteric testing portfolio, offering over 3,500 tests on its service list, including over 2,300 hematology tests. More than 1,100 test items were developed entirely in-house, and about 2,400 were developed by or licensed from external third parties. Kindstar Global provides a full range of testing services in specialized fields of hematology, genetic and rare diseases, infectious diseases, tumors, neurology and gynecology related diseases.

As the Chinese legal adviser to co-sponsors and the underwriter, Jingtian & Gongcheng’s legal team provided one-stop, end-to-end legal services including conducting Chinese legal due diligence, assisting in the third-party due diligence, visiting laboratories on-site, analyzing and resolving critical legal issues, participating in the preparation of IPO application documents, assisting in answering inquiries from the regulator. The team was engaged in the listing of Kindstar Global, overcame the obstacles brought on by the pandemic and safeguarded the successful IPO of the company, thus gaining unanimous recognition from the client and other intermediaries.